MX2021012568A - Preparacion de combinacion farmaceutica que comprende ezetimiba y losartan. - Google Patents

Preparacion de combinacion farmaceutica que comprende ezetimiba y losartan.

Info

Publication number
MX2021012568A
MX2021012568A MX2021012568A MX2021012568A MX2021012568A MX 2021012568 A MX2021012568 A MX 2021012568A MX 2021012568 A MX2021012568 A MX 2021012568A MX 2021012568 A MX2021012568 A MX 2021012568A MX 2021012568 A MX2021012568 A MX 2021012568A
Authority
MX
Mexico
Prior art keywords
ezetimibe
losartan
pharmaceutical combination
combination preparation
dissolved
Prior art date
Application number
MX2021012568A
Other languages
English (en)
Inventor
Yong Il Kim
Ho Taek Im
Hyuk Jun Cho
Min Wook Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2021012568A publication Critical patent/MX2021012568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una preparación de combinación farmacéutica que comprende ezetimiba y losartán. Cuando la preparación de combinación farmacéutica se disuelve en una solución de pH 4.0 a 5.0 durante 10 minutos, la cantidad disuelta de losartán es 5,700 µg o menos, y la cantidad disuelta de ezetimiba es 270 µg o más. La disolución en una solución de pH 4.0 a 5.0 se lleva a cabo en las condiciones de una temperatura de 37°C y un método de paletas de 50 rpm en 500 mL de regulador de pH de acetato de conformidad con la Farmacopea de Estados Unidos para la preparación de combinación farmacéutica que comprende 20 mg de ezetimiba y 183 mg de losartán.
MX2021012568A 2019-04-18 2020-04-07 Preparacion de combinacion farmaceutica que comprende ezetimiba y losartan. MX2021012568A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190045295A KR102500643B1 (ko) 2019-04-18 2019-04-18 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
PCT/KR2020/004694 WO2020213868A1 (ko) 2019-04-18 2020-04-07 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제

Publications (1)

Publication Number Publication Date
MX2021012568A true MX2021012568A (es) 2021-11-12

Family

ID=72838309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012568A MX2021012568A (es) 2019-04-18 2020-04-07 Preparacion de combinacion farmaceutica que comprende ezetimiba y losartan.

Country Status (8)

Country Link
EP (1) EP3957303A4 (es)
KR (1) KR102500643B1 (es)
CN (1) CN113747885B (es)
MX (1) MX2021012568A (es)
SG (1) SG11202111410SA (es)
TW (1) TWI827828B (es)
WO (1) WO2020213868A1 (es)
ZA (1) ZA202108268B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2179067A1 (en) 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
CN101594850A (zh) * 2006-12-21 2009-12-02 兰贝克赛实验室有限公司 降血脂药物组合物和及其制备方法
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2844233B1 (en) * 2012-05-01 2020-05-06 Althera Life Sciences, LLC Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR101977785B1 (ko) * 2014-06-25 2019-05-14 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
RU2724338C2 (ru) * 2015-06-30 2020-06-23 Ханми Фарм. Ко., Лтд. Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
CN106237334B (zh) * 2016-07-29 2019-05-24 珠海赛隆药业股份有限公司（长沙）医药研发中心 一种血管紧张素受体拮抗剂和米力农的复合物及其用途
EP3509603B1 (en) 2016-09-07 2024-01-03 Alyssum Therapeutics, Inc. Immune memory induction by platinum based compounds
KR102569271B1 (ko) * 2018-03-19 2023-08-23 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제

Also Published As

Publication number Publication date
SG11202111410SA (en) 2021-11-29
CN113747885B (zh) 2023-08-15
KR102500643B1 (ko) 2023-02-16
TW202103697A (zh) 2021-02-01
ZA202108268B (en) 2023-07-26
EP3957303A4 (en) 2022-11-23
TWI827828B (zh) 2024-01-01
CN113747885A (zh) 2021-12-03
EP3957303A1 (en) 2022-02-23
KR20200122517A (ko) 2020-10-28
WO2020213868A1 (ko) 2020-10-22

Similar Documents

Publication Publication Date Title
JP2015508774A5 (es)
JP2010525033A5 (es)
MA48486A (fr) Polymères liant les protons pour administration orale
US20060229262A1 (en) Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant
JP2018039810A5 (es)
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
EA202190115A1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения
CN109810263A (zh) 一种壳聚糖温敏凝胶的制备方法及应用
CN102772363B (zh) 一种含泊那珠利的溶液剂及其制备方法
MXPA02011389A (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y aplicacion.
RU2012148380A (ru) Композиция ацетаминофена
US20080233196A1 (en) Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles
MX2021012568A (es) Preparacion de combinacion farmaceutica que comprende ezetimiba y losartan.
RU2008146217A (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
RU2009147458A (ru) Концентрат эсмолола
RU2017114678A (ru) Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
PE20130180A1 (es) Soluciones farmaceuticas orales que comprenden telbivudina
Samad et al. Intracerebral coinfection with Burkholderia pseudomallei and Cryptococcus neoformans in a patient with systemic lupus erythematosus
CN103933033B (zh) 一种性能改善的甲硝唑氯己定洗剂
CA2838876A1 (en) Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
CN108158981A (zh) 一种利奈唑胺注射液
CN101732264B (zh) 一种头孢西酮钠冻干粉针剂
RU2010151994A (ru) Фармацевтические композиции, включающие карбоксивинильный полимер и повидоновый полимер
CN110151688A (zh) 一种盐酸氨溴索注射液组合物及其制备方法
RU2787754C1 (ru) Способ лечения маститов крупного рогатого скота